New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection.
SARS-CoV-2
infection
interleukin-17
interleukin-23
psoriasis
psoriatic arthritis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
31
10
2020
accepted:
04
12
2020
pubmed:
11
12
2020
medline:
27
2
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Psoriasis is a chronic immune-mediated disease characterized by inflammation of skin (psoriasis) or joints (psoriatic arthritis) or both, resulting from a dysregulation in particular of the T helper (Th)17 functions. There is no available cure for psoriasis, and a life-long treatment is needed to control signs and symptoms. Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL-23/IL-17 axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, focusing on the risk of infections.
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14660Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: review and treatment of psoriasis. Dis Mon. 2019;65(3):51-90. https://doi.org/10.1016/j.disamonth.2018.06.001.
Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605-1613. https://doi.org/10.4049/jimmunol.1800013.
Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD011535. https://doi.org/10.1002/14651858.CD011535.pub3.
Nakamura M, Lee K, Jeon C, et al. Guselkumab for the treatment of psoriasis: a review of phase iii trials. Dermatol Ther (Heidelb). 2017;7(3):281-292. https://doi.org/10.1007/s13555-017-0187-0.
Ceccarelli M, Venanzi Rullo E, Vaccaro M, et al. HIV-associated psoriasis: epidemiology, pathogenesis, and management. Dermatol Ther. 2019;75(10):e12806. https://doi.org/10.1111/dth.12806.
Dattilo G, Imbalzano E, Casale M, et al. Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices. Angiology. 2017;69(1):31-37. https://doi.org/10.1177/0003319717699329.
Dattilo G, Borgia F, Guarneri C, et al. Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol. 2019;17:85-89.
Di Lernia V, Bonamonte D, Lasagni C, et al. Safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis. Pediatr Dermatol. 2016;33:530-535.
Di Lernia V, Guarneri C, Stingeni L, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2017;29(3):217-219. https://doi.org/10.1080/09546634.2017.1364692.
Di Lernia V, Bianchi L, Guerriero C, et al. Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation. Dermatol Ther. 2019;32:e13091. https://doi.org/10.1111/dth.13091.
Guarneri C, Bevelacqua V, Patterson JW, Tchernev G. Cutaneous and visceral leishmaniasis during anti-TNFα therapy. Wien Med Wochenschr. 2017;167:78-82.
Li X, Andersen KM, Chang H-Y, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic. Art Ther. 2020;79(2):285-291. https://doi.org/10.1136/annrheumdis-2019-216102.
Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726-1735. https://doi.org/10.1016/j.jid.2018.01.039.
Haddad A, Li S, Thavaneswaran A, Cook RJ, Chandran V, Gladman DD. The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts. J Rheumatol. 2016;43(2):362-366. https://doi.org/10.3899/jrheum.140067.
Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016;75(2):287-296. https://doi.org/10.1016/j.jaad.2016.04.005.
Cacciola I, Borgia F, Filomia R, et al. Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with direct-acting antiviral therapy. J Viral Hepat. 2020;27:333-337.
Mitchell MC, Friedman LS, McClain CJ. Medical management of severe alcoholic hepatitis: expert review from the clinical practice updates committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017;15(1):5-12. https://doi.org/10.1016/j.cgh.2016.08.047.
Trecker MA, Waldner C, Jolly A, Liao M, Gu W, J-AR D. Behavioral and socioeconomic risk factors associated with probable resistance to ceftriaxone and resistance to penicillin and tetracycline in Neisseria gonorrhoeae in Shanghai. PLoS ONE. 2014;9(2):e89458. https://doi.org/10.1371/journal.pone.0089458.
Deodhar A, Gottlieb AB, Boehncke W-H, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213-2224. https://doi.org/10.1016/S0140-6736(18)30952-8.
Torres T. Selective Interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on Risankizumab Drugs. 2017;77(14):1493-1503. https://doi.org/10.1007/s40265-017-0794-1.
Duncan JR, Orlowski TJ, Elewski BE. Safety of guselkumab in hepatitis B virus infection. Dermatol Online J. 2019;25(10):16.
Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D. Pharmacokinetics of tildrakizumab (MK-3222), an anti-IL-23 monoclonal antibody, after intravenous or subcutaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol. 2018;123(3):294-300. https://doi.org/10.1111/bcpt.13001.
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676-1684. https://doi.org/10.1111/jdv.15653.
Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-response relationships for the efficacy and safety of Risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet. 2019;59:575-589. https://doi.org/10.1007/s40262-019-00829-2.
Machado Á, Torres T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis (Auckl). 2018;8:83-92. https://doi.org/10.2147/PTT.S165943.
d'Ettorre G, Ceccarelli G, Andreotti M, et al. Analysis of Th17 and Tc17 frequencies and antiviral defenses in gut-associated lymphoid tissue of chronic HIV-1 positive patients. Mediators Inflamm. 2015;2015:395484-395411. https://doi.org/10.1155/2015/395484.
Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337-353. https://doi.org/10.1146/annurev-med-051914-021944.
Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):888. https://doi.org/10.1186/s13075-019-1882-2.
Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Psoriasis and inflammatory bowel disease. Dig Dis. 2019;37(6):451-457. https://doi.org/10.1159/000500116.
Warren RB, Barker JNWB, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2019;183:60-70. https://doi.org/10.1111/bjd.18623.
Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of Secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(suppl 1):23-28. https://doi.org/10.1159/000501989.
Cannavò SP, Papaianni V, Bartolotta A, Guarneri C. Secukinumab for psoriasis in a patient with familial mediterranean fever. Dermatol Ther. 2019;32:e13122.
Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855-861. https://doi.org/10.1080/14712598.2019.1622678.
Wu C-Y, Chiu H-Y, Tsai T-F. The seroconversion rate of quantiFERON-TB gold in-tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLoS ONE. 2019;14(12):e0225112. https://doi.org/10.1371/journal.pone.0225112.
Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):333-339. https://doi.org/10.1111/jdv.15242.
Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47-62. https://doi.org/10.1111/bjd.15015.
Glatt S, Taylor PC, McInnes IB, et al. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Ann Rheum Dis. 2019;78(8):1033-1040. https://doi.org/10.1136/annrheumdis-2018-214943.
Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with self-reported psoriatic arthritis from the psoriasis longitudinal assessment and registry (PSOLAR) treated with biologics. BMC Rheumatol. 2019;3(1):52. https://doi.org/10.1186/s41927-019-0094-3.
Siddiqui NS, Khan Z, Khan MS, et al. Trends in incidence and outcomes of Clostridium difficile colitis in hospitalized patients of febrile neutropenia: a nationwide analysis. J Clin Gastroenterol. 2019;53(9):e376-e381. https://doi.org/10.1097/MCG.0000000000001171.
Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect. 2013;66(2):115-128. https://doi.org/10.1016/j.jinf.2012.10.019.
Marley C, Hahi El Y, Ferreira G, Woods L, Ramirez Villaescusa A. Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in clinical practice research datalink. Hum Vaccine Immunother. 2019;15(10):2475-2481. https://doi.org/10.1080/21645515.2019.1589288.
Buonomo EL, Petri WA. The microbiota and immune response during Clostridium difficile infection. Anaerobe. 2016;41:79-84. https://doi.org/10.1016/j.anaerobe.2016.05.009.
Saleh MM, Frisbee AL, Leslie JL, et al. Colitis-induced Th17 cells increase the risk for severe subsequent Clostridium difficile infection. Cell Host Microbe. 2019;25(5):756-765.e5. https://doi.org/10.1016/j.chom.2019.03.003.
Gurczynski SJ, Moore BB. IL-17 in the lung: the good, the bad, and the ugly. Am J Physiol Lung Cell Mol Physiol. 2018;314(1):L6-L16. https://doi.org/10.1152/ajplung.00344.2017.
Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev. 2016;80(3):629-661. https://doi.org/10.1128/MMBR.00078-15.
Pavone P, Ceccarelli M, Taibi R, La Rocca G, Nunnari G. Outbreak of COVID-19 infection in children: fear and serenity. Eur Rev Med Pharmacol Sci. 2020;24(8):4572-4575. https://doi.org/10.26355/eurrev_202004_21043.
Guarneri C, Venanzi Rullo E, Gallizzi R, Ceccarelli M, Cannavò SP, Nunnari G. Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19. J Eur Acad Dermatol Venereol. 2020;34:e449-e450. https://doi.org/10.1111/jdv.16669.
Guarneri C, Venanzi Rullo E, Pavone P, et al. Silent COVID-19: what your skin can reveal. Lancet Infect Dis. 2020;1-1. https://doi.org/10.1016/S1473-3099(20)30402-3.
Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21(3):1-5. https://doi.org/10.1007/s40257-020-00514-2.
Mohammed S. Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity. J Dermatolog Treat. 2020;1-10. https://doi.org/10.1080/09546634.2020.1752886.
Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-1218. https://doi.org/10.1016/j.jaad.2020.03.031.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0.
Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double- edged sword? Lancet. 2020;395(10230):1111. https://doi.org/10.1016/S0140-6736(20)30691-7.
Payal Shah BS, John G, Zampella MD. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic. J Am Acad Dermatol. 2020;82(6):1-4. https://doi.org/10.1016/j.jaad.2020.03.056.
Talamonti M, Galluzzo M, Chiricozzi A, et al. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. J Eur Acad Dermatol Venereol. 2020. In press. https://doi.org/10.1111/jdv.16841.